An interventional study of Dehydroepiandrosterone and placebo(medical starch) in Subfertility, sponsored by The Affiliated Hospital of Inner Mongolia Medical University. Recruiting at 1 site in China. Open to female participants aged 21 Years to 42 Years. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by The Affiliated Hospital of Inner Mongolia Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing dehydroepiandrosterone in Infertility — 2 open to participants now, 2 under way, 1 of them phase 3. Dehydroepiandrosterone · Infertility.
Among the 13 studies testing dehydroepiandrosterone in Infertility, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2015, is one of 3 with no phase, and was the 7th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →2 of the 13 studies testing dehydroepiandrosterone in Infertility are open now, in 2 countries. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 18–35 · Women only
By country, each count listing its studies:
Dehydroepiandrosterone: first FDA approval 2016 (INTRAROSA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 21 Years to 42 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 7 · Phase 4 2
First in 2007; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 140 across the 13 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 9 most frequent:
The Affiliated Hospital of Inner Mongolia Medical University is the lead sponsor of 9 studies on the registry; 8 are open to participants now.
The Affiliated Hospital of Inner Mongolia Medical University has 1 study filed under Infertility — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing dehydroepiandrosterone in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the effect of DHEA for treatment of subfertile patients with poor ovarian reserve and post-treatment evaluation of IVF outcome.
The aim of this randomized controlled study is to compare the effect of DHEA and placebo on live birth rate in poor ovarian responders. Consecutive infertile women attending the subfertility clinic for IVF treatment will be approached. Those fulfilling the selection criteria would be recruited and a written consent will be obtained after detailed explanation and counseling.
Baseline assessment will be performed at early follicular phase (Day 2 or 3) at recruitment. Patient characteristics including age, body mass index (BMI), and smoking status would be recorded and blood test including follicular stimulating hormone (FSH), estradiol (E2), testosterone and anti-Müllerian hormone (AMH) would be checked. Pelvic scan will be performed to assess the total antral follicle count (AFC) and total ovarian volume.
Subjects will be randomized divided into two groups:
Ultrasound assessment will be repeated in follicular phase (D2 or 3) of every month or cycle followed by a IVF treatment using antagonist protocol based on our standard departmental regimen. Cycle characteristics including the dose of gonadotrophins use, duration of stimulation, number of oocytes obtained, number of fertilized embryos and good quality embryos will be recorded and follicular fluid will be saved for hormonal profiles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Poor ovarian responders are defined according to the Bologna criteria fulfilling 2 out of 3 of the following:
Exclusion Criteria:
DHEA is considered as health supplement and is available over the counter. Side effects are minimal at present dosage (25mg or 50mg tds).
Drug: Dehydroepiandrosterone
Medical starch is considered as medicine components. Side effects are minimal at present dosage.
Other: placebo(medical starch)
75mg/day, PO for 90 days
Also known as: DHEA
75mg/day, PO for 90 days
Live birth rate
Compare the live birth rate between DHEA group and placebo group
Time frame: Participants will be followed for live birth rate up to 1 year.
Pregnancy rate
Compare the pregnancy rate between DHEA group and placebo group
Time frame: Participants will be followed for pregnancy rate up to 1 year.
The record gives a start of Feb 2015, a primary completion of Dec 2023 and a completion of Dec 2024. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dehydroepiandrosterone
The Affiliated Hospital of Inner Mongolia Medical University